参考文献/References:
[1] Colilla S, Crow A, Petkun W,et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population[J]. Am J Cardiol,2013,112:1142-1147.
[2] 陈忠秀,白文娟,饶莉.经皮左心耳封堵术预防心房颤动患者血栓栓塞的研究进展[J].中国介入心脏病学杂志,2013,4:248-250.
[3] European Heart Rhythm Association,European Association for Cardio-thoracic Surgery,Camm AJ, et al.Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC)[J].Eur Heart J,2010,31:2369-2429.
[4] 黄从新,张澍,马长生,等.心房颤动:目前的认识和治疗建议——2012[J].中华心律失常学杂志,2012,16(4):246-289.
[5] Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation[J]. Ann Thorac Surg,1996,61:755-759.
[6] 杨延坤,郑宏,孙鑫.64排螺旋CT心脏增强扫描在左心耳解剖形态评价中的应用[J].实用放射学杂志,2014,30(4):584-587.
[7] Veinot JP,Harrity PJ,Gentile F,et al.Anatomy of the normal left atrial appendage: a quantitative study of age-related changes in 500 autopsy hearts: implications for echocardiographic examination[J].Circulation,1997,96:3112-3115.
[8] di Biase L,Santangeli P,Anselmino M,et al.Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation.Results from a multicenter study[J].J Am Coll Cardiol,2012,60: 531-538.
[9] Camm AJ,Lip GY,de Caterina R,et al.2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation[J]. Eur Heart J,2012,33:2719-2747.
[10] Ostermayer SH, Reisman M, Kramer PH, et al.Percutaneous left atrial appendage transcatheter occlusion(PLAATO system)to prevent stroke in high-risk patients with nonrheumatic atrial fibrillation: results from the international multi-center feasibility trials[J].J Am Coll Cardiol,2005,46:9-14.
[11] Bayard YL, Omran H, Neuzil P, et al.PLAATO(percutaneous left atrial appendage transcatheter occlusion)for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study[J]. EuroIntervention,2010,6:220-226.
[12] Park JW, Bethencourt A, Sievert H, et al.Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience[J].Catheter Cardiovasc Interv,2011,77:700-706.
[13] Urena M, Rodés-Cabau J, Freixa X, et al.Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy[J]. J Am Coll Cardiol,2013,62:96-102.
[14] Horstmann S, Zugck C, Krumsdorf U, et al.Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage[J]. Neurology,2014,82:135-138.
[15] Lam SC,Bertog S,Gafoor S,et al.Left atrial appendage closure using the Amulet device: an initial experience with the second generation Amplatzer cardiac plug[J].Catheter Cardiovasc Interv,2015,85:297-303.
[16] Holmes DR,Reddy VY,Turi ZG,et al.Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial[J].Lancet,2009,374:534-542.
[17] Reddy VY,Holmes D,Doshi SK,et al.Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF(PROTECT AF)clinical trial and the Continued Access Registry[J].Circulation,2011,123:417-424.
[18] Holmes DR, Kar S,Price MJ,et al.Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial[J].J Am Coll Cardiol,2014,64:1-12.
[19] Reddy VY,Möbius-Winkler S,Miller MA,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation:the ASAP Study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[J].J Am Coll Cardiol,2013,61:2551-2556.
[20] Lam YY. A new left atrial appendage occluder(Lifetech LAmbre Device)for stroke prevention in AF[J]. Cardiovasc Revasc Med,2013,14:134-136.
[21] 李双,徐大春,朱梦云,等.三种左心耳封堵器的初步植入经验[J].上海医学,2015,38:189-192.
[22] Bartus K,Han FT,Bednarek J,et al.Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience[J].J Am Coll Cardiol,2013,62:108-118.
[23] Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium[J]. J Am Coll Cardiol,2014,64:565-572.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[9]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[10]范新荣,等.心房颤动药物治疗的新靶点[J].心血管病学进展,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]
FAN Xinrong,ZENG Xiaorong,et al.Novel Targets of Pharmacological Therapies at Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):584.[doi:10.3969/j.issn.1004-3934.2015.05.015]